Structural effects and competition mechanisms targeting the interactions between p53 and MDM2 for cancer therapy

  title={Structural effects and competition mechanisms targeting the interactions between p53 and MDM2 for cancer therapy},
  author={Shuxia Liu and Yi-Zhao Geng and Shiwei Yan},
  journal={Frontiers of Physics},
Approximately half of all human cancers show normal TP53 gene expression but aberrant overexpression of MDM2 and/or MDMX. This fact suggests a promising cancer therapeutic strategy in targeting the interactions between p53 and MDM2/MDMX. To help realize the goal of developing effective inhibitors to disrupt the p53–MDM2/MDMX interaction, we systematically investigated the structural and interaction characteristics of p53 with inhibitors of its interactions with MDM2 and MDMX from an atomistic… 
Mechanism of Competition between Nutlin3 and p53 for Binding with Mdm2
This work investigates the detailed competition mechanism between Nutlin3 and p53 in their binding to Mdm2 and finds that Nutlin 3 binds faster than the p53 molecule to MDM2 to prevent p53 binding toMdm2 when Nutlins have equal distance from each other.
Design and In Silico Study of the Novel Small Molecular MDM2 Inhibitors
A novel 1,2,4-triazole based molecules were designed as MDM2 inhibitors and performed their in-silico study indicating the Lead 1a as a potential MDM 2 inhibitor and anti-cancer agent.
Common cancer mutations R175H and R273H drive the p53 DNA-binding domain towards aggregation-prone conformations.
It is found that both R175H and R273H mutants exhibit a well preserved β-sheet structure, but a larger hydrophobic surface area and higher loop flexibility than WT p53C, which is consistent with the structural features of aggregation-prone molten-globule states.
Motile parameters of cell migration in anisotropic environment derived by speed power spectrum fitting with double exponential decay
Cell migration through anisotropic microenvironment is critical to a wide variety of physiological and pathological processes. However, adequate analytical tools to derive motile parameters to


How Nutlin-3 disrupts the MDM2–p53 interaction: a theoretical investigation
Nutlin-3 blocks the p53-binding pocket of MDM2 and thus disrupts theMDM2–p53 interaction and helps to activate p53 pathway of apoptosis, which is relatively more stable than MDM 2– p53 interaction.
On the interaction mechanisms of a p53 peptide and nutlin with the MDM2 and MDMX proteins: A Brownian dynamics study
The results, therefore, provide new insight into the mechanism of p53/nutlin interactions with MDM2 and MDMX and could potentially have a broader impact on anticancer drug optimization strategies.
Efficient reactivation of p53 in cancer cells by a dual MdmX/Mdm2 inhibitor.
It is demonstrated that a dual small-molecule antagonist of Mdm2/MdmX can efficiently reactivate the p53 pathway in model cancer cells overexpressing MdmX and/or MDM2.
MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.
These findings offer a preclinical proof-of-concept that RG7112 is effective in treatment of solid tumors expressing wild-type p53, and a potent and selective member of the nutlin family of MDM2 antagonists currently in phase I clinical studies.
The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious.
The release of functional p53 from the inhibition by Mdm2 and Mdmx should in principle provide an efficient, nongenotoxic means of cancer therapy and hold the key to developing novel, highly effective, and selective drug candidates.
MDMX Overexpression Prevents p53 Activation by the MDM2 Inhibitor Nutlin*
Results suggest that MDMX is also a valid target for p53 activation in tumor cells and development of novel compounds that are MDMX-specific or optimized for dual-inhibition of MDM2 and MDMX are necessary to achieve full activation of p53 in tumor Cells.
Flexible lid to the p53-binding domain of human Mdm2: Implications for p53 regulation
NMR studies of apo-MDM2 have found that, in addition to Mdm2 residues 25–109 that form the well ordered p53-binding domain that was observed in the p52–Mdm2 complex, MDM2 residues 16–24 form a lid that closes over the p53 -binding site.
The Pharmacodynamics of the p53-Mdm2 Targeting Drug Nutlin: The Role of Gene-Switching Noise
The results suggest that dose-splitting may be ineffective at low doses and effective at high doses, due to the interplay among the existence of a threshold on the p53 level for its cell activity, the nonlinearity of the relationship between the bolus dose and the peak of active p53, and the relatively fast elimination of the drug.
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
The crystal structure of the 109-residue amino-terminal domain of MDM2 bound to a 15-Residue transactivation domain peptide of p53 revealed that MDM 2 has a deep hydrophobic cleft on which the p53 peptide binds as an amphipathic α helix, supporting the hypothesis thatMDM2 inactivates p53 by concealing its transactivationdomain.